糖尿病胫前色素沉着斑患者皮肤免疫细胞浸润及中医证型的相关性研究

注册号:

Registration number:

ITMCTR2200006117

最近更新日期:

Date of Last Refreshed on:

2022-06-13

注册时间:

Date of Registration:

2022-06-13

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

糖尿病胫前色素沉着斑患者皮肤免疫细胞浸润及中医证型的相关性研究

Public title:

Study of skin immune cell infiltration and TCM syndrome type in diabetic patients with pigmented pretibial pathes

注册题目简写:

English Acronym:

研究课题的正式科学名称:

糖尿病胫前色素沉着斑患者皮肤免疫细胞浸润及中医证型的相关性研究

Scientific title:

Study of skin immune cell infiltration and TCM syndrome type in diabetic patients with pigmented pretibial pathes

研究课题的正式科学名称简写:

Liu

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200060877 ; ChiMCTR2200006117

申请注册联系人:

刘信邦

研究负责人:

常柏

Applicant:

Liu Xinbang

Study leader:

Chang bai

申请注册联系人电话:

Applicant telephone:

13677123065

研究负责人电话:

Study leader's telephone:

13388039172

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

510835479@qq.com

研究负责人电子邮件:

Study leader's E-mail:

changbai1972@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

http://www.tmu.edu.cn/dxbyy/

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

http://www.tmu.edu.cn/dxbyy/

申请注册联系人通讯地址:

天津市北辰区环瑞北路6号天津医科大学朱宪彝纪念医院

研究负责人通讯地址:

天津市北辰区环瑞北路6号天津医科大学朱宪彝纪念医院

Applicant address:

Tianjin Medical University Chu Hsien-I Memorial Hospital

Study leader's address:

Tianjin Medical University Chu Hsien-I Memorial Hospital

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津医科大学朱宪彝纪念医院

Applicant's institution:

Tianjin Medical University Chu Hsien-I Memorial Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

ZXYJNYYkMEC2022-1

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

天津医科大学朱宪彝纪念医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tianjin Medical University Chu Hsien-I Memorial Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022/4/10 0:00:00

伦理委员会联系人:

王丽

Contact Name of the ethic committee:

Wang Li

伦理委员会联系地址:

天津市北辰区环瑞北路6号天津医科大学朱宪彝纪念医院

Contact Address of the ethic committee:

Tianjin Medical University Chu Hsien-I Memorial Hospital

伦理委员会联系人电话:

Contact phone of the ethic committee:

022-59562020

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津医科大学朱宪彝纪念医院糖尿病足科

Primary sponsor:

Department of Diabetic foot, Tianjin Medical University Chu Hsien-I Memorial Hospital

研究实施负责(组长)单位地址:

天津市北辰区环瑞北路6号天津医科大学朱宪彝纪念医院

Primary sponsor's address:

Tianjin Medical University Chu Hsien-I Memorial Hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津市

市(区县):

北辰区

Country:

China

Province:

Tianjin

City:

Beichen

单位(医院):

天津医科大学朱宪彝纪念医院

具体地址:

天津市北辰区环瑞北路6号天津医科大学朱宪彝纪念医院

Institution
hospital:

Tianjin Medical University Chu Hsien-I Memorial Hospital

Address:

Tianjin Medical University Chu Hsien-I Memorial Hospital

经费或物资来源:

自筹

Source(s) of funding:

self-raised

研究疾病:

糖尿病胫前色素沉着斑

研究疾病代码:

Target disease:

pigmented pretibial pathes

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

病例对照研究

Case-Control study

研究所处阶段:

Study phase:

I期临床试验

Phase I clinical trial

研究目的:

研究糖尿病胫前色素沉着斑与无黑斑糖尿病患者的组织病理学差异可以为临床治疗PPP提供新的靶点,并有可能借此找到与其他糖尿病并发症的关系,为糖尿病并发症的早期发现和治疗带来突发性的进展。

Objectives of Study:

The study of histopathological differences between diabetic patients with pretibial pigmented plaques and those without black spots can provide a new target for clinical treatment of PPP, and possibly find the relationship with other diabetic complications, thus bringing sudden progress in the early detection and treatment of diabetic complications.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

根据1999年WHO制定的糖尿病诊断标准:空腹血糖≥7mmol/L,糖化血红蛋白(HbA1c)≥6.5%,餐后2h血糖≥11.1mmol/L或随机血糖≥11.1mmol/L。胫前皮肤萎缩的、不规则的斑片状褐色色素沉着,经皮肤科医生查看排除湿疹、神经性皮炎、淤积性皮炎等。

Inclusion criteria

According to the criteria for the diagnosis of diabetes formulated by WHO in 1999, fasting blood glucose ≥7mmol/L, HbA1c ≥ 6.5%, 2h postprandial blood glucose ≥11.1mmol/L or random blood glucose ≥11.1mmol/L. Tibial anterior skin atrophy, irregular patchy brown pigmentation, by dermatologist check exclude eczema, neurodermatitis, stasis dermatitis, etc.

排除标准:

①1型糖尿病、特殊类型糖尿病;②合并DM急性并发症,如糖尿病酮症及酮症酸中毒,低血糖及低血糖休克,糖尿病高渗高血糖状态;③严重肝肾功能不全; ④近期发生急性心脑血管意外或重大创伤等应激事件;⑤恶性肿瘤病史;⑥妊娠或哺乳期;⑦近期服用过免疫抑制剂。

Exclusion criteria:

① Type 1 diabetes, special type diabetes; ② With acute complications of DM, such as diabetic ketoacidosis and ketoacidosis, hypoglycemia and hypoglycemic shock, diabetic hyperotonic hyperglycemia; ③ Severe hepatic and renal insufficiency; ④ Stress events such as acute cardio-cerebrovascular accident or major trauma occurred recently; ⑤ History of malignant tumor; ⑥ Pregnancy or lactation; ⑦ He has taken immunosuppressants recently.

研究实施时间:

Study execute time:

From 2022-06-01

To      2023-06-01

征募观察对象时间:

Recruiting time:

From 2022-06-01

To      2023-06-01

干预措施:

Interventions:

组别:

有/无糖尿病胫前色素沉着斑组

样本量:

100

Group:

pigmented pretibial pathes

Sample size:

干预措施:

干预措施代码:

0

Intervention:

no

Intervention code:

样本总量 Total sample size : 100

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津市

市(区县):

北辰区

Country:

China

Province:

Tianjin

City:

Beichen

单位(医院):

天津医科大学朱宪彝纪念医院

单位级别:

三甲

Institution/hospital:

Tianjin Medical University Chu Hsien-I Memorial Hospital

Level of the institution:

Top three hospitals

测量指标:

Outcomes:

指标中文名:

病理表现

指标类型:

主要指标

Outcome:

pathological feature

Type:

Primary indicator

测量时间点:

2022/7/1-2022/8/1

测量方法:

HE染色后光镜下观察

Measure time point of outcome:

2022/7/1-2022/8/1

Measure method:

HE staining was followed by light microscopy

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

胫前皮肤

组织:

Sample Name:

Pretibial skin

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 30
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数表法

Randomization Procedure (please state who generates the random number sequence and by what method):

random number table

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

No

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

No

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

No

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

No

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

No

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统